Cushing Syndrome
History, Diagnosis and Treatment
- 1st Edition - February 2, 2026
- Latest edition
- Editor: Constantine A. Stratakis
- Language: English
Cushing Syndrome: History, Diagnosis, and Treatment is written by top experts on the latest in genetics, molecular advances, and the diagnosis and treatment of Cushing syndr… Read more
World Book Day celebration
Where learning shapes lives
Up to 25% off trusted resources that support research, study, and discovery.
Description
Description
The book has a section dedicated to our patients with the patients’ experiences, which will add to the outcome research presented by the physicians. This is a must have reference for scientists and researchers with the latest information in diagnosing and treating this difficult-to-diagnose and difficult-to-treat condition and gives the clinician, a patient-centric approach to communicate with this particular group of patients.
Key features
Key features
- Provides comprehensive “how to” information for diagnosis and treatment
- Includes the latest information on genetics, all molecular advances, and new medical therapies
- Presents a patient-centric approach with an emphasis on patients’ perspectives and long-term effects of cortisol excess, well-being, and mental health
Readership
Readership
Table of contents
Table of contents
2. Exogenous CS (iatrogenic): most frequent uses of glucocorticoids and outcomes, including recommendations for recovery (post-chemotherapy, asthma treatments, chronic use on rheumatoid and/or skeletal disorders)
3. Endogenous CS: causes and genetics
4. CS and malingering: Munchausen syndrome and Muncausen-by-proxy: cases, diagnosis, and outcomes
5. Non-tumorous functional hypercortisolemia (pseudo-CS): causes and long-term issues
6. Cushing disease: pituitary tumors causing CS: genetics, molecular advances, diagnosis, and treatment
7. Inferior Petrosal Sinus Sampling: to do or not to do
8. CRH test: to do or not to do
9. All about dexamethasone testing in CS
10. ACTH-independent CS: adrenal tumors causing CS: genetics, molecular advances, diagnosis, and treatment
11. Ectopic ACTH or CRH-producing tumors and CS: genetics, syndromes, molecular advances, diagnosis, and treatment
12. Animal models of CS: what do they teach us?
13. Medical therapies for CS
14. Surgical issues for a patient with CS: techniques, complications, and recovery
15. The patient with CS: perspectives written by patients; resources for patients
16. Cortisol exposure and mental health
17. CS and long-term effects on health, cognition, and function
Product details
Product details
- Edition: 1
- Latest edition
- Published: February 5, 2026
- Language: English
About the editor
About the editor
CS
Constantine A. Stratakis
Professor Constantine A Stratakis is an internationally known medical geneticist, endocrinologist, translational investigator and executive leader with a unique combination of skills and experience in science, healthcare, clinical trials, molecular research and genetics, policy, government regulations, and patient advocacy. Prof. Stratakis served as the Chief Scientific Officer of ELPEN Pharmaceuticals, in Athens (GR) and directed the efforts to build a new ELPEN Research Institute that is due to open in 2026-27, while he also runs human genetics and precision medicine at IMBB, FORTH, in Heraklion, GR. Most recently he was selected to coordinate the Hellenic Network for Precision Medicine in Molecular Oncology (EDIMO; https://edimo.gr/) and his laboratory (www.digenia.gr) participates in 3 other funded Precision Medicine programs: the 2 networks for Cardiac and Neurodegenerative diseases in Greece and the Health Hub program for the digital transformation of Medicine (2022-26).
His basic training was in medicine (Athens, GR 1989), pediatrics, endocrinology and medical genetics (Paris, France 1988, Georgetown University, Washington DC, USA 1990-1996) and holds a Medical Doctor’s, a Doctorate in Medical Sciences, and two honorary PhD degrees, in addition to being a graduate of the University of Maryland School of Public Policy Executive Leadership program (2012).
As an executive leader, Prof. Stratakis led the National Institutes of Health (NIH/NICHD) genetics and endocrinology programs and the NICHD intramural research program (1,100 employees, $200M/year budget) in the United States, for more than 18 years where he trained more than 200 trainees. He is highly sought as a Mentor, speaker, teacher, a patient advocate, and a trusted and highly respected advisor for a wide-range of issues, across various sectors of the healthcare and innovation in life sciences ecosystem.
As an investigator, Prof. Stratakis has worked on the genetics of solid tumors and has identified a number of predisposing genetic defects, including a disease that bears his name (Carney-Stratakis syndrome). He has authored more than 850 publications and served in major Editorial roles of leading journals. He received the 1999 Award for Excellence in Published Clinical Research and the 2009 Ernst Oppenheimer Award both from the US Endocrine Society, and a number of other honors, including NIH Merit and Director’s Awards; he also has been named Visiting Professor in academic centers around the world. He is the recipient of the 2019 Dale Medal from the British Endocrine Society and received the 2018 International Award of the European Society of Pediatric Endocrinology (ESPE). He was named honorary member of the Hellenic Society of Cardiology (2017) and the Hellenic Endocrine Society (2019) for his work on the genetics of hypertension and endocrine diseases, respectively. He holds two honorary doctoral degrees from the Universities of Liege, Belgium (2013) and Athens, Greece (2017).
Prof. Stratakis served as the 2018-2019 President of the Society of Pediatric Research (SPR) in the US. In addition to the SPR, he is an elected member of American Pediatric Society (APS), the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP). Dr. Stratakis most recently was instrumental in the launching of the new NICHD Strategic Plan (2020-2024) that emphasizes Precision Medicine, and the use of large data in predictive healthcare.
Prof. Stratakis is dedicated to advances in Science, and he is an exquisite teacher and a marvelous communicator with many interviews in the lay press supporting Science. He is also a tireless advocate of early-stage investigators, diversity and equity.
Finally, Prof. Stratakis is a constant innovator with 4 patents and already involved in start-ups: ASTREA Health, HealthspanDigital. Sterotherapeutics, are three companies that he is involved or founded, all in the last 3 years (2022-2025).